$59.93
0.88% yesterday
Nasdaq, May 20, 10:00 pm CET
ISIN
US09061G1013
Symbol
BMRN

Biomarin Pharmaceutical Stock price

$59.93
+1.28 2.18% 1M
-2.63 4.20% 6M
-5.80 8.82% YTD
-17.12 22.22% 1Y
-19.79 24.82% 3Y
-34.11 36.27% 5Y
-68.04 53.17% 10Y
Nasdaq, Closing price Tue, May 20 2025
+0.52 0.88%
ISIN
US09061G1013
Symbol
BMRN
Sector
Industry

Key metrics

Market capitalization $11.49b
Enterprise Value $10.83b
P/E (TTM) P/E ratio 22.24
EV/FCF (TTM) EV/FCF 17.35
EV/Sales (TTM) EV/Sales 3.71
P/S ratio (TTM) P/S ratio 3.93
P/B ratio (TTM) P/B ratio 1.98
Revenue growth (TTM) Revenue growth 17.99%
Revenue (TTM) Revenue $2.92b
EBIT (operating result TTM) EBIT $626.54m
Free Cash Flow (TTM) Free Cash Flow $624.18m
Cash position $1.27b
EPS (TTM) EPS $2.70
P/E forward 17.18
P/S forward 3.66
EV/Sales forward 3.45
Short interest 3.01%
Show more

Is Biomarin Pharmaceutical a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Biomarin Pharmaceutical Stock Analysis

Unlock Scores for Free

Analyst Opinions

31 Analysts have issued a Biomarin Pharmaceutical forecast:

25x Buy
81%
6x Hold
19%

Analyst Opinions

31 Analysts have issued a Biomarin Pharmaceutical forecast:

Buy
81%
Hold
19%

Financial data from Biomarin Pharmaceutical

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
2,922 2,922
18% 18%
100%
- Direct Costs 636 636
11% 11%
22%
2,286 2,286
20% 20%
78%
- Selling and Administrative Expenses 868 868
8% 8%
30%
- Research and Development Expense 701 701
10% 10%
24%
718 718
126% 126%
25%
- Depreciation and Amortization 91 91
13% 13%
3%
EBIT (Operating Income) EBIT 627 627
194% 194%
21%
Net Profit 524 524
155% 155%
18%

In millions USD.

Don't miss a Thing! We will send you all news about Biomarin Pharmaceutical directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Biomarin Pharmaceutical Stock News

Neutral
PRNewsWire
5 days ago
Acquisition is Strong Strategic Fit for BioMarin, Adding INZ-701, a Phase 3 Enzyme Replacement Therapy Being Developed for Treatment of ENPP1 Deficiency First Pivotal Data Readout in Children Expected in Early 2026 with Potential Launch in 2027; Additional Clinical Programs to Expand to Patients of all Ages  Potential First-in-Disease Treatment for ENPP1 Deficiency Conference Call and Webcast S...
Neutral
PRNewsWire
9 days ago
New data in children under 5 years with achondroplasia showed treatment with VOXZOGO was associated with improvement in tibial bowing, a common cause of pain and impaired function  Data from the largest retrospective, multi-year observational study of more than 600 children and adults with hypochondroplasia found significantly higher rates of comorbidities, surgeries and overall doctor visits  ...
Neutral
Seeking Alpha
19 days ago
BioMarin Pharmaceutical Inc. (BMRN) Q1 2025 Earnings Call Transcript
More Biomarin Pharmaceutical News

Company Profile

BioMarin Pharmaceutical, Inc. is a biotechnology company, which engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline include Vosoritide (BMN 111) for Achondroplasia and Valoctocogene Roxaparvovec (BMN 270) for Hemophilia A. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997 and is headquartered in San Rafael, CA.

Head office United States
CEO Alexander Hardy
Employees 3,040
Founded 1997
Website www.biomarin.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today